Optimising thyroid replacement and evidence-based lifestyle interventions should be explored as first-line approaches before considering GLP-1 medications
Novel GLP-1R agonists currently under development include HRS9531, a dual GLP-1/GIP receptor agonist being evaluated in overweight or obese individuals with T2DM, which has shown promising results in a Phase 2 study [172]
If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug
Regular exercise, a balanced diet, limiting salt, reducing stress, and getting quality sleep all have proven effects on blood pressure